Syapse Continues Rapid Growth, Secures Financing Led By The Social+Capital Partnership

Syapse established as one of the largest repositories of human genome and clinical data, enabling the processing of over 3,000 human genomes per quarter.

Palo Alto, CA -- January 22, 2013 -- Syapse, announced unprecedented momentum in helping laboratories and clinics generate and use next-generation sequencing to diagnose and treat patients. Syapse software is now involved in the processing of over 3,000 patient genomes and thousands of transcriptome, proteome, immunome, and microbiome profiles per quarter. With 100 billion omics and clinical data points and 10 terabytes of data under management, Syapse is one of the largest repositories of human molecular profiles.

"We are excited to be working with Syapse on our shared goal of bringing genomics into everyday clinical practice to truly enable personalized medicine," said Randy Scott, co-founder and CEO of InVitae. "Achieving our goal requires a new information infrastructure to connect genomic and clinical information across millions of individuals. Syapse provides that infrastructure."

Syapse Discovery provides an end-to-end solution for companies and laboratories deploying next-generation sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver their diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations.

Syapse software is used by sequencing system providers to help them develop their sequencers and deliver more integrated user experiences. Syapse is compatible with all major sequencers, and is a launch partner of Illumina's BaseSpace. Syapse software is used by new system providers like GenapSys to automate sequencing workflows and cloud connect machines to centrally track genomic profiles and quality metrics.

Syapse announced today that it has raised a Series A round of venture capital funding led by The Social+Capital Partnership ("Social Capital"). As part of this investment, Social Capital founder Chamath Palihapitiya has joined Syapse's Board of Directors. "The keystone to human health lies in the interpretation of genomic information. Syapse is making a quantum leap in creating this future," said Chamath Palihapitiya. "We are excited to receive an investment from Social Capital.

the leader in bringing omics into routine medical use,With a renown group of investors like Mayo Clinic, Eli Broad, and Li Ka-shing, Social Capital is at the forefront of driving discontinuous improvement in healthcare," said Glenn Winokur, co- founder and CEO of Syapse.

In recognition of Syapse's growing presence, in early 2013 Syapse will present at the Personalized Medicine World Conference, the Burrill Digital Health Meeting, and the Bio-IT World Conference. Syapse and InVitae will jointly present a use case at Bio-IT World Conference about Syapse enabling InVitae's clinical genomic diagnostic test.

About Syapse

Syapse is disrupting healthcare by bringing omics into routine medical use. Built on a powerful cloud-based semantic data platform, Syapse applications enable the generation and use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. Led by an experienced, multidisciplinary team of entrepreneurs, software developers, and scientists, Syapse was founded at Stanford University and is backed by The Social+Capital Partnership. For more information, please see

The Social+Capital Partnership ("Social Capital") is a partnership of the world's most renowned philanthropists, technologists and capitalists utilizing venture capital as a force to create massive value and change on a global scale. The Partnership is based in Palo Alto, California.


[email protected] (650) 924-1461

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.